i-NEED: NEw migrainE Drugs Database

Plain-language summary

This study aims to track, through a database, the effects of newer migraine drugs (anti-CGRP monoclonal antibodies, gepants, a sumatriptan-naproxen combination, and ditans). It is open to people aged 18 and older with episodic or chronic migraine. It is a study without an assigned phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

IRCCS San Raffaele Roma

Intervention

anti-CGRP monoclonal antibodies, gepants, combination of sumatriptan and naproxen, ditan

Start date

3/24/2022

Estimated completion

12/31/2026

Countries

Italy

Related genes

Locations

• Milan, Italy
• Rome, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Age more or equal 18 years;
* Males and females;
* Willingness to sign the informed consent;
* Episodic migraine for the use of drug indicated for migraine attack
* High frequency episodic migraine, at least 8 days per month of disabling migraine in the past 3 months;
* Chronic migraine, according to the ICHD-III criteria;

Exclusion Criteria:

* Other headaches different than migraine;
* Known intolerance to the eccipients;
* Vascular disease or Raynaud.